Ristocetin A (sulfate)
(Synonyms: Ristomycin III) 目录号 : GC16058
An antibiotic used in clotting assays
Cas No.:90831-71-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ristocetin A, a glycopeptide related to vancomycin, is an antibiotic produced by the microorganism Nocardia lurida[1].
Ristocetin A is currently in clinical use to treat bacterial infections [1]. Ristocetin A is an antibiotic which can be used to treat staphylococcal infections. The side effects of ristocetin A include thrombocytopenia and platelet agglutination. Ristocetin A has been used in two assays: the ristocetin cofactor assay and the ristocetin-induced platelet aggregation assay. These two assays could be used to diagnosis the von Willebrand disease and other bleeding disorders [2, 3]. The structural features of Ristocetin A are similar to vancomycin.
References:
[1] Pearson A J, Heo J N. Approaches to the fully functionalized DEF ring system of ristocetin A via highly selective ruthenium-promoted SNAr reaction[J]. Organic letters, 2000, 2(19): 2987-2990.
Hawks G H. Antibiotic therapy of staphylococcal infections[J]. Canadian Medical Association journal, 1965, 93(16): 848.
[3] Castaman, G. ,Hillarp, A. and Goodeve, A. Laboratory aspects of von Willebrand disease: Test repertoire and options for activity assays and genetic analysis. Haemophilia 20(suppl 4), 65-70 (2014).
| Cas No. | 90831-71-3 | SDF | |
| 别名 | Ristomycin III | ||
| 化学名 | ristomycin A, monosulfate | ||
| Canonical SMILES | CC1C(O)C(N)CC(OC2C3C(NC(C(OC)=O)C4=CC(O)=CC(OC5C(O)C(O)C(O)C(CO)O5)=C4C6=C(O)C=CC(C(NC(C7C8=CC(OC9=CC=C(C(O)C%10C(NC(C(N7)=O)C%11=CC(OC%12=C(O)C=CC(C(N)C(N%10)=O)=C%12)=C(C)C(O)=C%11)=O)C=C9)=C(OC%13C(OC%14C(OC%15C(O)C(O)C(O)CO%15)C(O)C(O)C(CO)O%14)C(O)C( | ||
| 分子式 | C95H112N8O44 • SO4 | 分子量 | 2166.0 |
| 溶解度 | DMF: Soluble,DMSO: Soluble,Ethanol: Soluble,Methanol: Soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.4617 mL | 2.3084 mL | 4.6168 mL |
| 5 mM | 0.0923 mL | 0.4617 mL | 0.9234 mL |
| 10 mM | 0.0462 mL | 0.2308 mL | 0.4617 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet